Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial
American Heart Journal Jul 18, 2019
Sharma A, et al. - Given the risk for bleeding and subsequent adverse non–bleeding-related events among patients with a recent acute coronary syndrome (ACS) receiving oral antiplatelets and anticoagulants, researchers assessed clinical events during a 30-day period after Thrombolysis in Myocardial Infarction (TIMI) major/minor bleeding. This post hoc analysis included 7,392 high-risk patients (median follow-up 241 days) with a recent ACS who were randomized to apixaban or placebo. During follow-up, TIMI major/minor bleeding was reported in 153 (2.1%) patients. They noted significantly increased risk of ensuing ischemic events and mortality in correlation to bleeding. This risk was noted irrespective of antithrombotic or anticoagulant strategy. Bleeding risk was comparable for patients receiving apixaban plus aspirin vs those receiving thienopyridine plus aspirin.
Sign-up to continue reading. It is free & takes less than 2 mins
45 lakhs+ doctors trust M3 globally
Free & unlimited access to original articles and quizzes
Secure: we never sell your data
Why join our Market Research Panel?
- 10K+ Doctors participated in 40+ Indian and Global studies in 2018
- Average honorarium per study was Rs. 1,600 and total honoraria as high as Rs. 12,000 was earned by a Doctor